SLC6A3 and major depressive disorder: Dopamine transporter reuptake inhibition may ameliorate MDD patients’ anhedonia and the decline in positive emotion and improve cognition reward motivation and goal-oriented behavior (Zhang et al., 2014; Carvalho et al., 2016; Guo et al., 2018; Meder et al., 2019).